Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qifu Yin is a traditional Chinese medicine (TCM) herbal decoction first described in the Ming Dynasty text 'Jingyue Quanshu'. It is traditionally indicated for the treatment of 'dementia' (chi dai) caused by deficiency of the heart and spleen or kidney essence. The formula is composed of seven primary botanical ingredients: Panax ginseng, Rehmannia glutinosa, Atractylodes macrocephala, Angelica sinensis, Ziziphus jujuba var. spinosa, Glycyrrhiza uralensis, and Citrus reticulata. Modern clinical research focuses on its application in cognitive disorders, including post-stroke cognitive impairment and Alzheimer's disease. Its mechanism is thought to involve neuroprotection through the reduction of oxidative stress, inhibition of neuroinflammation, and modulation of the cholinergic system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qifu Yin.